当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Diabetic kidney disease 2.0: the treatment paradigm shifts.
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2019-09-05 , DOI: 10.1016/s2213-8587(19)30253-0
Richard E Gilbert 1
Affiliation  

By contrast with the major developments in cardiovascular therapeutics, an entire generation has gone by with no new treatments to effectively stem the rising tide of kidney failure in people with diabetes. For those individuals unfortunate enough to have end-stage kidney disease, fewer than half will be alive after 5 years of maintenance haemodialysis. And for those whose kidney function is less impaired, every incremental reduction in estimated glomerular filtration rate (eGFR) or rise in albuminuria exponentially increases the risk of death or cardiovascular morbidity.

中文翻译:

糖尿病肾病2.0:治疗范式转移。

与心血管疗法的重大发展形成鲜明对比的是,整整一代人都没有新的疗法来有效遏制糖尿病患者不断增长的肾衰竭趋势。对于那些不幸患上终末期肾脏疾病的人,在维持血液透析5年后,其存活率还不到一半。对于肾脏功能受损较少的人,估计的肾小球滤过率(eGFR)的每一次逐渐降低或蛋白尿的增加都将导致死亡或心血管疾病的风险成倍增加。
更新日期:2019-10-16
down
wechat
bug